CL3-20098-070 - Efficacy and safety of agomelatine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder [more info]

CL2-38093-009 - Safety and efficacy of S 38093 and donepezil, during 4 weeks, in patients with mild to moderate Azheimer’s Disease. An international, multi-centre, randomised, double-blind, placebo-controlled, phase II add-on study [more info]

Dosage of repaglinide in plasma samples from the BIA-91067-115 clinical trial of Bial. [more info]

Dosage of S- and R-warfarin in plasma samples from the BIA-91067-116 clinical trial of Bial [more info]

A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures [more info]

A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/day Monotherapy in Subjects with Partial-onset Seizures [more info]

A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease [more info]

A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Phychosis in Parkinson’s Disease [more info]

A randomized, double-blind, parallel group, multi-center, comparative, flexible dose trial of pregabalin versus gabapentin as adjunctive therapy in subjects with partial seizures. [more info]

A 52-week open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-to-moderate alzheimer´s disease (REFLECT-4). [more info]

Dosage of antidiabetics in plasma samples from the BIA-2093-206 clinical trial [more info]

A randomized, comparative, double-blind, parallel-Group, Multicenter, Monotherapy, study of Pregabalin (Lyrica) and Lamotrigine (Lamictal) in patients with newly diagnosed partial seizures [more info]

Areas of expertise

• Studies of absolute bioavailability of a drug.
• Elaboration of documentation to submit for the regulatory authorities, associated with bioequivalence studies.
• Bioequivalence studies of pharmaceutical products having the same drug in the same formulation or different formulations.
• Elaboration of documents for clinical trials.
• Development and validation of analytical methods.
  Dosage of drugs in the finished product or during the manufacturing process and in biological matrixes.
• Clinical studies on the variability of different batches of preparation from a single manufacturer.
  Chemical control of raw materials and manufactured products.
• Scientific advisor of reviews or reports for the introduction of drugs in Portugal and the European Union.